As pioneers of polymerase chain reaction (PCR) technology, scientific and clinical excellence is in our DNA.
Roche systems and assays are the preferred choice in clinical trials across the industry and are also trusted with keeping the blood supply safe.
Beyond pathogen detection, our suite of viral load monitoring assays and leadership in HPV Primary Screening empower laboratories to better inform clinical decisions.
Further advances in oncology testing with the cobas® EGFR Mutation Test v2 bring clearer results and confident decisions to those who are most vulnerable.
Our comprehensive assay menu is held to the highest performance standards to deliver confidence in every result.
Roche’s industry-leading systems offer proven performance across a range of throughputs to meet your unique needs.
Working hand-in-hand, we expanded our efforts to provide innovative diagnostics solutions to those who need it most.
We give healthcare providers the confidence to safeguard the moments that matter most, at every stage of her life.
Roche’s dual target approach for HIV-1 viral load monitoring improves result accuracy for better decision-making.
Learn about cobas® HPV, the first FDA-approved, CE-marked HPV DNA test for cervical cancer screening.
Our cobas® EGFR Test v2 allows you to detect EGFR mutations in plasma and FFPE tissue to determine mutation status.
Real-time detection and discrimination of HIV, HCV, and HBV in a single test for blood donor screening.
Roche assays have played an integral role in defining and shaping treatment guidelines, establishing treatment cut-offs, and as a benchmark for assay performance.
Flexibly expand, customize, automate, and standardize your laboratory’s LDT portfolio with our diverse offering of nucleic acid purification and qPCR solutions.
The first commercial test for SARSCoV-2 detection, enabling expedited coronavirus testing to meet urgent medical needs.
The Global Access Program now includes HIV, MTB, HBV/HCV, and HPV for countries with the highest burden of disease.
The first commercial test for the detection of the Zika in human plasma intended for use in screening blood donations.
High-throughput, reliable and accurate differential diagnosis of COVID-19 and influenza
Change is nothing new in healthcare, the pace of it is. The Molecular Work Area is purposefully designed to meet your current and future needs. Now, laboratories of all sizes and disciplines can harness the potential of molecular testing to elevate the value they deliver across their organization.
The Molecular Work Area is built upon Roche’s industry-leading systems, comprehensive assay menu, advanced pre-analytical instruments, and flexible IT solutions. The flexible design allows laboratories to eliminate virtually all manual steps with automation, consolidation, integration and standardization.
Experience a new paradigm in workflow efficiency. Roche offers a range of standalone, physical, and virtual automation solutions that minimise laboratory inefficiency and maximise organisational value.
Get an integrated view of your laboratory ecosystem. With advanced IT automation, you can confidently meet key performance indicators, raise the bar on laboratory automation, and do more with your time.
Change can be a challenge, but it does not have to be. From process analysis and laboratory design to change management and data analysis, Roche Healthcare Consulting has the expertise your laboratory needs for
an effective and streamlined transformation.
Specialized and local experts can help you to optimize laboratory processes with the right solutions for your current and future needs. Our consultants will work with you to improve turnaround time (TAT), reduce errors, and create
efficiencies, while measuring performance criteria –financial, clinical, quality or personnel – every step of the way.
Roche’s commitment to excellence, corporate stability, and delivery of innovation makes us the ideal choice for the future of your laboratory.
We employ more engineers and service personnel than any other diagnostic provider, and you can be confident that our products and applications will continue to be supported into the future.
We look forward to speaking with you.